Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms

Abstract

Cathepsin L, a cysteine protease, is overexpressed in human tumor cells and plays a major role in melanoma progression. Our aim was herein to identify molecular mechanisms, which contribute to its overexpression. We found that cathepsin L protein expression correlated with mRNA level in tumor cells. Therefore, we focused on mechanisms involved in cathepsin L mRNA regulation. CpG island was localized in the 5′ region of cathepsin L gene that encompassed regulatory regions identified as essential for promoter activity. CpG dinucleotides, not methylated in any melanoma cells analysed, were methylated in a B lymphoma cell line, which poorly express cathepsin L. Our data demonstrate that in lymphoma cells, cathepsin L silencing was methylation-dependent. Furthermore, gene amplification was involved in cathepsin L overexpression in one melanoma cell line, while transcriptional mechanisms but not mRNA stability are responsible of cathepsin L overexpression in others melanoma cells. In addition, NF-Y, Sp1, Sp2 and Sp3 transcription factors, essential to basal cathepsin L transcription, are not directly involved in overexpression. Thus, our data provides the first demonstration that cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Abdollahi A, Getts LA, Sonoda G, Miller PD, Taguchi T, Godwin AK et al. (1999). J Soc Gynecol Investigat 6: 32–40.

  • Agirre X, Vizmanos JL, Calasanz MJ, Garcia-Delgado M, Larrayoz MJ, Novo FJ . (2003). Oncogene 22: 1070–1072.

  • Amuthan G, Biswas G, Zhang SY, Klein-Szanto A, Vijayasarathy C, Avadhani NG . (2001). EMBO J 20: 1910–1920.

  • Barel M, Fiandino A, Lyamani F, Frade R . (1989). Proc Natl Acad Sci USA 86: 10054–10058.

  • Charron M, DeCerbo JN, Wright WW . (2003). Biol Reprod 68: 1649–1656.

  • Chauhan SS, Popescu NC, Ray D, Fleischmann R, Gottesman MM, Troen BR . (1993). J Biol Chem 268: 1039–1045.

  • Frade R, Balbo M, Barel M . (2000). Cancer Res 60: 6585–6589.

  • Frade R, Rodrigues-Lima F, Huang S, Xie K, Guillaume N, Bar-Eli M . (1998). Cancer Res 58: 2733–2736.

  • Frade R . (1999). Immunopharmacology 42: 39–45.

  • Gardiner-Garden M, Frommer M . (1987). J Mol Biol 196: 261–282.

  • Grzybowska EA, Wilczynska A, Siedlecki JA . (2001). Biochem Biophys Res Commun 288: 291–295.

  • Guillaume-Rousselet N, Jean D, Frade R . (2002). Biochem J 367: 219–227.

  • Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD et al. (2002). Am J Pathol 161: 125–134.

  • Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB et al. (1998). Proc Natl Acad Sci USA 95: 12410–12415.

  • Ishidoh K, Taniguchi S, Kominami E . (1997). Biochem Biophys Res Comm 238: 665–669.

  • Jean D, Bar-Eli M, Huang S, Xie K, Rodrigues-Lima F, Hermann J, Frade R . (1996). Cancer Res 56: 254–258.

  • Jean D, Guillaume N, Frade R . (2002). Biochem J 361: 173–184.

  • Jean D, Hermann J, Rodrigues-Lima F, Barel M, Balbo M, Frade R . (1995). Biochem J 312: 961–969.

  • Jean D, Rodrigues-Lima F, Cassinat B, Hermann J, Cabane J, Frade R . (1997). Immunol Lett 58: 107–112.

  • Kamboj RC, Pal S, Raghav N, Singh H . (1993). Biochimie 75: 873–878.

  • Kawada A, Hara K, Kominami E, Hiruma M, Noguchi H, Ishibashi A . (1997). Arch Dermatol Res 289: 87–93.

  • Kirschke H, Eerola R, Hopsu-Havu VK, Bromme D, Vuorio E . (2000). Eur J Cancer 36: 787–795.

  • Krueger S, Kellner U, Buehling F, Roessner A . (2001). Cancer Gene Ther 8: 522–528.

  • Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J et al. (2003). Cancer Gene Ther 10: 141–151.

  • Luca MR, Bar-Eli M . (1998). Histol Histopathol 13: 1225–1231.

  • Malone CS, Miner MD, Doerr JR, Jackson JP, Jacobsen SE, Wall R et al. (2001). Proc Natl Acad Sci USA 98: 10404–10409.

  • Mao X, Hamoudi RA . (2000). Cancer Genet Cytogenet 122: 87–92.

  • Ohashi K, Naruto M, Nakaki T, Sano E . (2003). Biochim Biophys Acta 1649: 30–39.

  • Pesole G, Liuni S . (1999). Trends Genet 15: 378.

  • Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R . (2004). Cancer Res 64: 146–151.

  • Sriraman V, Richards JS . (2004). Endocrinology 145: 582–591.

  • Suske G . (1999). Gene 238: 291–300.

  • Turk V, Turk B, Guncar G, Turk D, Kos J . (2002). Adv Enzyme Regul 42: 285–303.

Download references

Acknowledgements

This work was supported by INSERM, Ligue Contre le Cancer (Comité Ile-de-France et Comité de l'Essonne) and Association de Recherche contre le Cancer (ARC, Villejuif).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Jean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jean, D., Rousselet, N. & Frade, R. Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene 25, 1474–1484 (2006). https://doi.org/10.1038/sj.onc.1209196

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209196

Keywords

This article is cited by

Search

Quick links